At the Ophthalmology Innovation Summit (OIS XIII), Dr. Jing-feng Huang, the founder of Seinda Pharmaceutical Corp, shared significant research findings on tear biomarkers and introduced the novel mechanism dry eye drug SY-201 and the in vitro diagnostic product for tear biomarkers.
If you wish to learn more and watch the full content, please click on the video link below.